GRCL News

The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion.  Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The company provides customer service outsourcing and end-to-end customer experience and digital technology solutions and...read more

In a staggering start to 2021, two biotechs and 28 SPACs raised over $7.1 billion in the first week of the new year. Activity should remain high as new filings continued to flood the IPO pipeline.   Chinese cancer biotech Gracell Biotechnologies (GRCL) priced above the range to raise $209 million at a $1.3 billion market cap. Gracell is developing CAR-T...read more

Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, raised $209 million by offering 11 million ADSs at $19, above the range of $16 to $18. The company originally planned to offer 8.8 million ADSs before increasing the offering to 11 million ADSs on Thursday morning. Gracell Biotechnologies plans to list on the Nasdaq under the symbol...read more

Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Suzhou, China-based company now plans to raise $187 million by offering 11 million ADSs at a price range of $16 to $18. The company had previously filed to offer 8.8 million ADSs at the same range. At the midpoint,...read more